U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07137390) titled 'Phase Ib/II Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer' on Aug. 15.
Brief Summary: To apply its findings as rationale needed for a subsequent registration trial towards a novel indication for systemic treatment of resectable, lung-limited metastatic CRC.
Study Start Date: Feb. 28, 2026
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer
Intervention:
DRUG: Regorafenib
Given Orally
DRUG: Lorigerlimab
Given Orally
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content...